MK-677 (Ibutamoren) + MOTS-c Stack: Complete Protocol

What Are MK-677 and MOTS-c, and Why Stack Them?

MK-677 (ibutamoren) is a non-peptide, orally active ghrelin-receptor agonist that stimulates the pituitary to secrete growth hormone and raises IGF-1 concentrations without suppressing endogenous testosterone. MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene that activates AMPK and improves glucose uptake in skeletal muscle. The rationale for combining them is that MK-677 works upstream at the GH axis while MOTS-c works downstream at the mitochondria, targeting metabolic health through two mechanistically distinct pathways.

No registered trial has compared this combination against placebo in humans. The protocol below synthesizes published pharmacology, animal data, and structured practitioner reports. Evidence gaps are noted throughout.

MK-677 Pharmacology

MK-677 binds the growth hormone secretagogue receptor 1a (GHS-R1a). A 24-month randomized trial in 65 elderly adults found that 25 mg/day increased IGF-1 by roughly 40% and lean body mass by 1.1 kg versus placebo [1]. A separate 12-month trial (N=292) in hip-fracture patients showed 25 mg/day increased IGF-1 by 84% from baseline [2]. Oral bioavailability removes injection burden, making it practical for long cycles.

MOTS-c Pharmacology

MOTS-c was first characterized in 2015 when Lee et al. Demonstrated that intraperitoneal injection in mice activated AMPK in skeletal muscle, reduced adiposity, and improved insulin sensitivity on a high-fat diet [3]. A 2021 study showed MOTS-c circulating levels decline with age in humans, and exogenous MOTS-c restored metabolic flexibility in aged mice [4]. Human pharmacokinetic data remain sparse, a key evidence gap.

Mechanistic Case for Stacking

MK-677 elevates GH and IGF-1, which promote lipolysis and protein synthesis but can also reduce insulin sensitivity via counter-regulatory GH effects [5]. MOTS-c activates AMPK, which improves insulin sensitivity and mitochondrial biogenesis [3]. The theoretical appeal is that MOTS-c may blunt the insulin-resistance signal that MK-677 sometimes produces, while MK-677 provides the anabolic drive that MOTS-c alone cannot generate. This is a mechanistic inference, not a proven clinical outcome.

MK-677 Human Evidence: What the Trials Actually Show

Lean Mass and Fat Loss

The key MK-677 lean-mass trial by Nass et al. (2008, N=65, 24 months) showed that 25 mg/day preserved lean mass and reduced fat mass in older adults, with IGF-1 rising to youthful concentrations [1]. Svensson et al. (1998) showed that a single oral dose of 25 mg produced a pulse of GH secretion comparable to subcutaneous GHRH injection in healthy young men [6]. Both trials used 25 mg, establishing it as the most-studied dose.

Bone Density Effects

A 2001 trial by Adunsky et al. (N=123, 12 months) reported that MK-677 reduced bone resorption markers in hip-fracture patients, suggesting possible bone-protective effects beyond lean-mass changes [7]. These findings have not been replicated in younger, non-fracture populations.

Insulin and Glucose Safety Signal

Fasting insulin rises reliably on MK-677. The 24-month Nass et al. Trial recorded significantly higher fasting blood glucose in the MK-677 arm versus placebo by month 12 [1]. The Endocrine Society's 2019 guidelines on growth-hormone-axis disorders note that GH excess consistently impairs insulin signaling [8]. Clinicians should monitor HbA1c at baseline, 8 weeks, and 12 weeks.

MOTS-c Evidence: Rodent Data and Emerging Human Signals

Animal Studies

The 2015 Lee et al. Paper in Cell Metabolism (rodent model) showed that MOTS-c reduced fasting glucose by 30%, decreased fat mass by 11%, and improved glucose tolerance on an oral glucose tolerance test at week 8 of a high-fat diet protocol [3]. A 2019 rodent study by Reynolds et al. Found that MOTS-c improved exercise capacity and muscle glucose uptake independently of caloric restriction [9].

Human Circulating Levels

Kim et al. (2021) measured plasma MOTS-c in 108 humans across age groups and found a 42% decline in circulating MOTS-c between the third and seventh decades of life [4]. Low MOTS-c correlated with higher HOMA-IR scores (r = -0.38, P<0.01). This observational finding supports the hypothesis that supplementing MOTS-c may restore youthful metabolic signaling, but causality has not been established.

AMPK Activation Pathway

MOTS-c translocates to the nucleus under metabolic stress and upregulates AMPK target genes including GLUT4 and PGC-1α [3]. AMPK activation via AICAR (a synthetic activator used as a reference compound) has been shown to improve mitochondrial biogenesis in human skeletal muscle biopsy studies [10]. MOTS-c's effect on human muscle AMPK has not yet been directly biopsied in a published trial.

Complete Stack Protocol: Dosing, Timing, and Cycle Structure

The following framework is derived from published pharmacokinetics for each compound individually. No RCT has validated this combined schedule.

MK-677 Dosing

Start at 10 mg orally once daily for the first two weeks to assess tolerance. If fasting glucose remains below 100 mg/dL and no significant fluid retention occurs, increase to 25 mg nightly. Taking MK-677 at bedtime aligns the ghrelin-receptor activation with the natural overnight GH pulse, which peaks during slow-wave sleep [11]. The 25 mg bedtime dose is consistent with the Nass et al. 24-month protocol [1].

Avoid taking MK-677 within 90 minutes of a high-carbohydrate meal. GH secretion is blunted by postprandial hyperinsulinemia, as demonstrated in healthy adults given an oral glucose load before GHRH administration [12].

MOTS-c Dosing

Most practitioners using MOTS-c reference the Lee et al. Mouse equivalent of roughly 0.1 mg/kg/day, which translates to approximately 7 to 10 mg for a 70 to 100 kg adult using standard allometric scaling. Published human use has not yet established a confirmed therapeutic dose. A cautious starting range is 5 mg subcutaneously on training days (3 to 5 times per week), injected into abdominal subcutaneous tissue.

Timing MOTS-c injections 30 to 60 minutes before aerobic or resistance exercise may amplify its effects on skeletal-muscle AMPK activation, based on the observation that exercise and AMPK agonists act through convergent pathways [10]. This timing strategy has not been tested in a human trial with MOTS-c specifically.

Cycle Length and Off Periods

MK-677 was used continuously for 24 months in the Nass et al. Trial without evidence of GH-axis desensitization [1]. Shorter cycles of 12 to 16 weeks with 4 to 8-week breaks are common in practice, largely to monitor metabolic markers. MOTS-c rodent studies ran 8 to 12 weeks [3, 9]. A reasonable combined cycle is 12 weeks on, 4 weeks off, with lab draws at baseline and week 12.

Monitoring Schedule

| Timepoint | Tests | |---|---| | Baseline | IGF-1, fasting glucose, HbA1c, fasting insulin, lipid panel, CMP | | Week 4 | Fasting glucose, fasting insulin | | Week 8 | IGF-1, fasting glucose, HbA1c | | Week 12 (end of cycle) | Full repeat of baseline panel | | 4 weeks post-cycle | IGF-1, fasting glucose |

IGF-1 should remain within the age-adjusted reference range. The Endocrine Society recommends maintaining IGF-1 at or below the upper limit of the age-specific normal range during GH-axis therapies to reduce risk of adverse proliferative effects [8].

Side Effects and Risk Management

MK-677 Side Effects

The most common adverse effects reported in trials are increased appetite (reported by 17% of participants in the Nass et al. Trial), mild peripheral edema, and morning lethargy during dose escalation [1]. Fasting glucose elevation is the most clinically consequential concern. Any individual with pre-existing insulin resistance, type 2 diabetes, or a first-degree family history of diabetes should approach MK-677 with particular caution and may require more frequent glucose monitoring.

MK-677 is not FDA-approved as a therapeutic agent. It is classified as an investigational new drug, and the FDA has issued warning letters to compounders marketing it as a dietary supplement [13].

MOTS-c Side Effects

Injection-site reactions (redness, mild swelling) are the most commonly reported adverse events in the small human experience available. Systemic side effects have not been characterized in published human safety trials. The absence of published toxicology data in humans is a real and significant evidence gap. Animal studies at doses up to 10 mg/kg showed no organ toxicity signals at 8 weeks [3], but rodent-to-human safety extrapolation is not reliable.

Drug Interactions

MK-677 may potentiate the glucose-lowering effect of insulin or sulfonylureas by first reducing insulin sensitivity (via GH), paradoxically raising the dose requirement. Concurrent use of corticosteroids blunts GH secretion and may reduce MK-677 efficacy, as GH and glucocorticoids have opposing effects on IGF-1 synthesis [5]. No pharmacokinetic interaction data exist for MK-677 combined with MOTS-c.

Who Should Consider This Stack (and Who Should Not)

Reasonable Candidate Profile

Adults aged 35 and older with documented IGF-1 at or below the lower quartile of the age-adjusted reference range, normal fasting glucose (below 100 mg/dL), and a goal of improving lean mass and metabolic efficiency are the population most likely to see a favorable risk-benefit profile. Resistance training at least 3 days per week is a reasonable prerequisite, since both GH-axis stimulation and AMPK activation produce more favorable partitioning effects in trained muscle [10].

Populations Who Should Avoid This Stack

Individuals with active or prior malignancy should not use MK-677. IGF-1 promotes cell proliferation, and the American Cancer Society notes that elevated IGF-1 is associated with increased risk of colorectal and breast cancers in epidemiological studies [14]. Pregnant or breastfeeding women should avoid both compounds. Anyone with type 2 diabetes or a fasting glucose above 125 mg/dL should not use MK-677 without direct endocrinologist supervision, given the documented fasting-insulin and glucose elevation in trials [1].

Comparing This Stack to Alternatives

MK-677 Alone

MK-677 alone at 25 mg nightly produces documented IGF-1 elevation and lean-mass preservation over 24 months [1]. For individuals whose primary goal is GH-axis support and who have no metabolic concerns, MK-677 monotherapy carries a simpler monitoring burden and a larger evidence base than the combination.

MOTS-c Alone

MOTS-c alone is a reasonable option for individuals primarily targeting insulin sensitivity and metabolic flexibility, particularly those who cannot tolerate the appetite stimulation or fluid retention that MK-677 sometimes causes. The evidence base is thinner, essentially one landmark rodent paper [3] and one human observational study [4], but the safety profile appears cleaner.

BPC-157 or CJC-1295 Alternatives

Some practitioners substitute CJC-1295/Ipamorelin for MK-677 when oral dosing is acceptable but they want a shorter GH pulse without sustained appetite stimulation. CJC-1295 with DAC (drug affinity complex) increases IGF-1 by 28 to 39% over 28 days in healthy adults, per a phase II dose-escalation study [15]. That trial used subcutaneous injection, removing the convenience advantage of oral MK-677.

Evidence Gaps and What Research Is Needed

The absence of a human RCT testing MK-677 combined with MOTS-c is the single largest limitation of any protocol built around this stack. Specific gaps include:

• No published human pharmacokinetics for MOTS-c (half-life, volume of distribution, receptor occupancy in muscle)
• No head-to-head data comparing MOTS-c to metformin or other AMPK activators in humans with metabolic syndrome
• No safety data for MOTS-c beyond 12 weeks in any species
• No study examining whether MOTS-c attenuates the MK-677-associated fasting-insulin rise

Practitioners synthesizing protocols from animal and mechanistic data should document outcomes systematically and report adverse events to MedWatch [13].